| Therapeutic | Lunsekimig1 |
| Target 1 | IL13 |
| Heavy Chain 1 | DVQLVESGGGVVQPGGSLRLSCAASGRTFSSYRMGWFRQAPGKEREFVAALSGDGYSTYTANSVKGRFTISRDNSKNTVYLQMNSLRPEDTALYYCAAKLQYVSGWSYDYPYWGQGTLVTVSS |
| Light Chain 1 | na |
| 100% seqID Fv 1 Structure | None |
| 99% seqID Fv 1 Structure | None |
| 95-98% seqID Fv 1 Structure | None |
| Target 2 | IL13 |
| Heavy Chain 2 | EVQLVESGGGVVQPGGSLRLSCAASGFTFNNYAMKWVRQAPGKGLEWVSSITTGGGSTDYADSVKGRFTISRDNSKNTLYLQMNSLRPEDTALYYCANVPFGYYSEHFSGLSFDYRGQGTLVTVSS |
| Light Chain 2 | na |
| 100% seqID Fv 2 Structure | None |
| 99% seqID Fv 2 Structure | None |
| 95-98% seqID Fv 2 Structure | None |
Follow these links to our prediction tools:
| Format | Trispecific and Pentavalent (sc-5-VH); Bispecific entry |
| Isotype | na;na |
| Highest Clinical Trial (Feb '25) | Phase-II |
| Estimated Status (Feb '25) | Active |
| Recorded Developmental Technology | |
| INN Year Proposed | 2023 |
| INN Year Recommended | 2024 |
| Companies Involved | Sanofi |
| Conditions Approved | na |
| Conditions Active | Asthma, Inflammation |
| Conditions Discontinued | na |
| Notes | Pentavalent; targets two different epitopes on IL13 and TSLP. Fv1 Chimeric: Alpaca/human. |
Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]
SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]
Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]
